How much does products liability insurance cost for a CDMO with $20M revenue?

A Texas pharma CDMO at $20M revenue with a typical product mix (mid-volume sterile injectable plus oral solid dose, no controlled substances, A.M. Best A-rated carrier appetite) generally lands in the $15,000-$55,000 range annually for a standalone $5M-$10M products liability tower. The spread is wide because the underlying risk profile varies enormously.

The lower end of the range corresponds to oral solid dose manufacturing only, clean claims history (5+ years no claims), single-sponsor or low-concentration sponsor mix, and clean FDA inspection history. The upper end corresponds to sterile injectable manufacturing, multi-sponsor exposure across innovator and generic pharma, and any 483 observations or warning letters in the last 24 months.

Five factors drive most of the premium variance: (1) product class — sterile injectable manufacturing carries roughly 2-3x the premium of oral solid dose at the same revenue; (2) sponsor concentration — a CDMO with a single sponsor accounting for 60%+ of revenue prices materially differently than a CDMO with 10 sponsors and no concentration; (3) claims history — any products liability claim in the last 5 years tightens carrier appetite and increases premium materially; (4) FDA inspection history — clean inspection record drives the lower end of the range, 483 observations or warning letters drive the upper end; (5) carrier appetite — admitted carriers writing the class are a narrow set, and surplus-lines placement through wholesale brokers prices 15-40% higher.

The single biggest variance driver in 2026 is whether the CDMO does any work for sponsors with current controlled-substance products (Schedule II-V). Carriers writing pharma contract manufacturing have tightened underwriting on controlled substance exposure post-opioid litigation; CDMOs touching the class often face 30-50% premium increases on otherwise identical risk profiles.

Products liability is one line of about eight a Texas CDMO at $20M typically carries. The full program premium with all required coverage lines — CGL, products, professional liability/E&O if development scope exists, workers comp, auto, umbrella, cyber, property — generally runs $50,000 to $140,000 annually at this revenue band. The products line is the largest single component but not the only one.

Buyers focused only on the products line miss the structural questions about endorsement coordination (additional insured for products and completed operations on the right form, primary/non-contributory wording, waiver of subrogation, 30-day notice), professional liability coverage for development-services scope, and recall coverage adequacy. The premium difference between an optimally structured program and a generic placement at the same total dollars is frequently a 6-figure exposure at first claim.

The most expensive component of CDMO insurance at this revenue band is often not the premium but the cost of premium for coverage that fails when needed. A standard manufacturers products policy without recall extension, without products/completed-ops AI endorsement, or without primary/non-contributory wording satisfies the COI on paper but fails the actual sponsor MSA on a strict reading. The premium difference between such a policy and an optimally structured policy is frequently $5,000-$15,000 annually; the difference at first claim can run into seven figures of uncovered exposure.

The diagnostic check before binding: have a specialist review your top 3 sponsor MSAs against the policy form you're about to bind, not just the certificate of insurance. If the MSA requires CG 20 37 specifically and the policy attaches only CG 20 10, the COI looks fine but the program will not satisfy the contract on the additional-insured-for-products dimension.

Underwriting submissions for CDMO products liability typically take 7-14 days from submission to quote, depending on carrier complexity and any outstanding documentation requests. The standard submission package includes: 3 years loss runs across all lines, current declarations pages, list of top 10 sponsors by revenue with contract terms summarized, FDA inspection history (most recent 3 inspections at minimum), product mix breakdown by class (sterile injectable, oral solid, etc.), and current SOPs for product release.

Our free coverage review (linked in the contact form) covers the submission preparation, market access to specialty carriers writing the CDMO class, and gap analysis against actual sponsor MSAs before binding. End-of-business-day SLA on initial response.